NPS Pharma


Wedbush Reiterates Neutral On NPS Pharmaceuticals Despite FDA Approval For Natpara

Wedbush analyst David Nierengarten was out with some neutral comments on NPS Pharmaceuticals (NASDAQ:NPSP), following the news that the company’s Natpara has been approved by the FDA to …

Oppenheimer Comments On NPS Pharma In Light Of Shire Takeover

Oppenheimer healthcare analyst Rohit Vanjani weighed in today with his thoughts on NPS Pharma (NASDAQ:NPSP), after the company and Shire (NASDAQ:SHPG) announced a definitive merger agreement whereby …

NPS Pharma: Rems Concern? Overblown, Says Canaccord

In a research report released today, Canaccord analyst John Newman reiterated a Buy rating on shares of NPS Pharma (NASDAQ:NPSP) with a $42 price target, following concerns …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts